Objectif
Immune-mediated, non-communicable diseases, such as autoimmune diseases, allergic diseases and asthma, are chronic disorders in which the interaction between exposome and immune system plays a pivotal role. As prevalence and societal costs of these diseases are rising in the EU, a holistic approach is needed.
The EXIMIOUS consortium—gathering high-level experts in immunology, toxicology, clinical medicine, environmental hygiene, epidemiology, bioinformatics and sensor development—will bring about a new way of assessing the human exposome by linking innovative ways of characterizing and quantifying multiple and combined environmental exposures (exposomics) with high-dimensional immunophenotyping and -profiling platforms to map the (early) immune effects induced by these exposures (immunomics).
In several cohorts—covering the entire lifespan, including prenatal life—we will extensively map exposome, immune system (immunome), other omics and clinical and socio-economic data, using two main methodologies—one starting from the exposome, the other starting from health effects—that ‘meet in the middle’. Novel bioinformatics tools, based on systems immunology and machine learning, will be used to integrate and analyse these huge datasets and to construct ‘immune fingerprints’ that reflect a person’s lifetime exposome and identify ‘immune fingerprints’ that are early signs of poor health and predictors of disease at the individual level.
We will build a multifaceted toolbox for researchers, policy makers, clinicians and the general public containing the exposome/immunome tools developed during the project to help assess the impact of the exposome on the immune system at the level of individuals and populations. This will allow policy makers to grasp the components of the exposome that needs to be prioritized to be able to design targeted preventive policies to reduce healthcare and socioeconomic costs, leading to greater wellbeing for the EU population.
EXIMIOUS will work together with the other projects (EXPANSE, HEAP, ATHLETE, EQUAL-LIFE, LONGITOOLS, EPHOR, REMEDIA and HEDIMED) funded within the Human Exposome programme call H2020-SC1-BHC-2018-2020, in order to achieve collaboration and synergy.
Champ scientifique
- medical and health sciencesclinical medicinepneumologyasthma
- medical and health scienceshealth sciencespublic healthepidemiology
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
- medical and health sciencesbasic medicinetoxicology
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
3000 Leuven
Belgique
Voir sur la carte
Participants (15)
3500 Hasselt
Voir sur la carte
0456 Oslo
Voir sur la carte
2100 Kobenhavn
Voir sur la carte
9052 Gent
Voir sur la carte
3001 Leuven
Voir sur la carte
1348 Louvain La Neuve
Voir sur la carte
Participation terminée
CB22 3AT Cambridge
Voir sur la carte
BT7 1NN Belfast
Voir sur la carte
3400 Hillerod
Voir sur la carte
9220 Aalborg Ost
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
08035 Barcelona
Voir sur la carte
8000 Aarhus C
Voir sur la carte
540139 Targu Mures
Voir sur la carte
8008 ZURICH
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
CB2 1TN Cambridge
Voir sur la carte